Pharmaceuticals, Biotechnology and Life Sciences
VDPHL01 has the potential to be the first and only extended-release oral minoxidil for women and men with pattern hair…
Research confirms muscle stem cell dysfunction impairs polarity and impedes production of myogenic progenitors during fetal development Findings solidify AAK1…
WINREVAIR demonstrated a statistically significant and clinically meaningful reduction in the primary endpoint of pulmonary vascular resistance (PVR) compared to…
First-in-class isogenic model of the human neurovascular unit offers unparalleled human relevance for studying blood-brain barrier drug transport and neuroinflammation.…
Advocate Health National Center for Clinical Trials to remove barriers and improve access to breakthrough treatments CHARLOTTE, N.C.–(BUSINESS WIRE)–Advocate Health…
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission…
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding…
-At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus standard-of-care endocrine monotherapy- -These unprecedented results support…
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe,…
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in Europe Omlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is…